Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo, as the company tries to catch up to a lead in the space established by rival Novo.















